Second Cancer Risk in Female Survivors of Hodgkin Lymphoma: A National Cohort Analysis Across Treatment Eras
Year: 2026
Type: article
Study design: Observational Study
Abstract: PURPOSE: Subsequent primary malignancies (SPMs) are the leading cause of long-term treatment-related mortality in Hodgkin lymphoma (HL). Although treatments have evolved substantially over recent decades, few studies have demonstrated reductions in SPM risks following modern treatments, nor how such changes should inform survivorship care and screening. We analyzed SPM risks in a large female cohort of childhood and adult patients with HL treated over a 60-year period. MATERIALS AND METHODS: This population-based cohort study included 7,428 women diagnosed with HL before age 36 years in England and Wales from 1954 to 2010, with follow-up through 2018. SPMs were ascertained via national cancer registry linkages. Standardized incidence ratios (SIRs), absolute excess risks, and multivariable models were used to assess temporal trends and associations with treatment. RESULTS: During a median follow-up of 20.2 years, 1,200 women developed 1,467 invasive cancers (SIR, 3.3 [95% CI, 3.1 to 3.5]), most commonly breast, lung, and thyroid cancers. Solid tumor risks were the highest following radiotherapy, with a strong dose-dependent response. Alkylator use with radiotherapy was associated with reduced risks of breast cancer but increased risks of GI cancers. Solid cancer risks decreased by 25% between treatment periods 1954-1989 and 2000-2010. The decrease was attenuated and nonsignificant after adjustment for radiotherapy but not affected by adjustment for chemotherapy. No decline was observed for hematologic malignancies. Cumulative incidence of SPMs reached 36% at 50 years. CONCLUSION: Female patients treated in more recent eras have a substantially lower long-term risk of solid SPMs largely attributable to the reduced use, dose, and improvement in radiotherapy. Nevertheless, persistently elevated risks remained beyond 50 years of follow-up, particularly for lung and breast cancer, underscoring the need for lifelong surveillance and targeted screening of survivors.
Source: Journal of Clinical Oncology
DOI: 10.1200/jco-26-00418
Authors: Aislinn Macklin-Doherty, David Cunningham, Ian Chau, Andrew Bates, Kim Benstead, Mark Bower, Murray Brunt, Paul Fields, George Follows, Christopher P. Fox, John Frew, John G. Gribben, Peter Hoskin, Clive Irwin, Lisa Lowry, John Radford, Isabel Syndikus, Anjali Zarkar, Emma Thomas, Amy Berrington de Gonzalez, Michael E. Jones, Anthony J. Swerdlow
Institutions: Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Royal Marsden Hospital, NIHR Biomedical Research Centre at The Royal Marsden and the ICR, University Hospital Southampton NHS Foundation Trust, Gloucestershire Hospitals NHS Foundation Trust, Imperial College London, Keele University, Guy's and St Thomas' NHS Foundation Trust, University of Cambridge, Addenbrooke's Hospital, Nottingham University Hospitals NHS Trust, University of Nottingham, Freeman Hospital, Queen Mary University of London, Barts Cancer Institute, University of Manchester, Mount Vernon Cancer Centre, The Christie NHS Foundation Trust, University Hospital Coventry, Clatterbridge Cancer Centre NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, St James's University Hospital
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W7225903292
